MedTrace Logo

Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors

NCT02227654 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2023-03-02

No results posted yet for this study

Summary

The present investigation will prospectively evaluate whether serial transvaginal ultrasonography with Morphology Index (MI) can further reduce false positive results by more accurately distinguishing benign from malignant ovarian tumors. If there is no change in the detection of true positive cases, the result will be an increase in the positive predictive value of ovarian cancer screening.

Conditions

  • Ovarian Neoplasms

Interventions

PROCEDURE

Abnormal Ovarian Ultrasound

Ultrasound

Sponsors & Collaborators

  • Lucille P. Markey Cancer Center at University of Kentucky

    collaborator OTHER

  • Frederick R. Ueland, M.D.

    lead OTHER

Principal Investigators

  • Frederick R. Ueland, M.D. · Markey Cancer Center, University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-12
Primary Completion
2022-09-07
Completion
2022-09-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02227654 on ClinicalTrials.gov